Category: News & Events

Medication Therapy Management (MTM) is an essential service designed for individuals who are navigating the complexities of multiple medications. This program is particularly beneficial for those dealing with several health…Continue readingMedday and Happy Family Store Offer Medication Therapy Management Services

Paris, France, April 27 2015 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces it will webcast its post-AAN Clinical Trials Plenary Session, on…Continue readingMedDay to webcast results of its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis

– Identification of novel molecular mechanisms of action of MD1003 in neurodegeneration Paris, France, 14 September 2016 – MedDay, a biotechnology company focused on the treatment of nervous system disorders,…Continue readingPositive Preclinical Data with MD1003 (high dose pharmaceutical grade biotin) in X-Linked Adrenoleukodystrophy to be presented at European Committee for Treatment and Research in Multiple Sclerosis 2016

~ Phase III data to be disclosed at AAN Annual Meeting in Clinical Trials Plenary Session on April 24th 2015~ Paris, France, April 7 2015 – MedDay, a biotechnology company…Continue readingMedDay provides update on pioneering pivotal Phase III study design in Progressive Multiple Sclerosis

Paris, January 14th, 2015 – MedDay, an emerging biotechnology company focused on the treatment of nervous system disorders, today provides an update on the progress of its pipeline including its…Continue readingMedDay provides update on pipeline progress

Paris, France, 7 October 2015 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces that, during the European Committee for Treatment and Research in Multiple…Continue readingMedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis

MedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with Progressive Multiple Sclerosis – Improvement of Clinical Global Impression of change evaluated by the…Continue readingMedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with Progressive Multiple Sclerosis

First drug capable of reversing disease progression in patients with progressive MS Extension phase data demonstrate sustained efficacy up to 2 years Both studies support efficacy specifically in patients with…Continue readingMedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN

First time a drug has decreased the rate of disease progression in addition to improving a significant proportion of patients with progressive MS Primary endpoint met (p=0.0051) Mean EDSS change…Continue readingMedDay reports positive pivotal Phase III study results with MD1003 in patients with Progressive Multiple Sclerosis

Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation. Funds will drive a confirmatory phase…Continue readingMedDay Secures €34 Million ($38.5M) New Funding